Early renal changes in hemizygous and heterozygous patients with Fabry's disease.
about
Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry diseaseReceptor-mediated endocytosis of α-galactosidase A in human podocytes in Fabry diseaseTriglycerides in the human kidney cortex: relationship with body sizeUnexpected Fabry disease in a renal allograft kidney: an underrecognized cause of poor allograft function.Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease.Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry RegistryScoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN).Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry diseaseRenal lipid metabolism and lipotoxicity.Update on role of agalsidase alfa in management of Fabry disease.Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapyAnderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous malesCharacterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial.Curvilinear bodies in hydroxychloroquine-induced renal phospholipidosis resembling Fabry disease.Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation.Light- and electron-microscopic histochemistry of Fabry's diseaseOne Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease.Substrate-specific gene expression profiles in different kidney cell types are associated with Fabry diseaseFoot process effacement with normal urinalysis in classic fabry disease.Agalsidase benefits renal histology in young patients with Fabry disease.Fabry disease: guidelines for the evaluation and management of multi-organ system involvement.Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry diseaseAssessment of renal pathology and dysfunction in children with Fabry disease.Fibrosis: a key feature of Fabry disease with potential therapeutic implicationsRenal complications of Fabry disease in childrenFabry disease in children and the effects of enzyme replacement treatment.Risk of death in heart disease is associated with elevated urinary globotriaosylceramide.Electron microscopy in end stage renal disease: a case of Fabry's disease.Lysosome dysfunction in the pathogenesis of kidney diseases.Fabry's disease: an example of cardiorenal syndrome type 5.Lysosomal delivery of therapeutic enzymes in cell models of Fabry disease.An open-label study to determine the pharmacokinetics and safety of migalastat HCl in subjects with impaired renal function and healthy subjects with normal renal function.Renal variant of Fabry disease with sporadic GLA gene mutation: role of early renal biopsy.Fabry disease in donor kidneys with 3- and 12-year follow-up after transplantation.Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy.Pathomechanisms of renal Fabry disease.X-chromosome inactivation in female patients with Fabry disease.Immunohistochemical diagnosis of Fabry nephropathy and localisation of globotriaosylceramide deposits in paraffin-embedded kidney tissue sections.Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience.
P2860
Q24650910-3E679463-6736-4731-B7E0-92BB093B45AFQ28477142-15FCC35E-5844-4C07-80CA-6013E931A933Q28542644-B3F96B7D-4695-4167-BDE6-BD19A9CEF69FQ30452805-374C5F34-C2D2-442F-8A69-4C81D9C96016Q33179389-DA985185-184E-4589-BD91-614653924291Q33645550-99731374-9A63-482D-8772-E19C00533AA5Q33683158-FD8FCF5F-4250-4DA8-8991-D68BC633EB79Q33988780-B46AD389-3954-4F78-9B08-86F76039F11EQ34489355-D871B1FF-0D1B-499F-961B-F3455BFF1113Q34825296-D367DF08-1434-4672-AEAF-F48A08049F1CQ34883178-75DDBB2D-9751-423E-9DAB-419F2F645CC3Q34945403-84897D4D-4A80-4A86-B4E7-CA05F79CA511Q35436303-F76E4D6E-E3E3-44DA-AB53-20F26191AE56Q35587768-19B60553-6DCD-4094-B246-9E4056ABBC3DQ35626557-FCEC5903-6A5D-463E-A4AA-2F4C10D8363EQ35788989-C06B878A-A9BC-4AA6-B1BB-309929FADA93Q35864092-C09F6995-CE1C-4EBE-8F19-F58390989130Q35990846-2F232CAC-34E8-4DAB-81C7-765231279745Q36089921-45328793-7E1E-4026-90FB-883C22254D35Q36433223-CD9CE7EA-F292-4930-A6E3-8EFD5B6AA26DQ36509288-8536494C-7EFB-4B31-A598-715EDE6A4334Q36596408-89AF300C-DF7D-4965-99DC-228CADE189D7Q36808226-2E24C503-FC49-4FD3-97A7-72829A72701DQ37007821-619477E9-ADDF-412B-A7CE-CC0D407AD9EEQ37113004-38A2F825-F1C0-4C42-893B-D0C53F26537FQ37265117-B177C703-1D69-4E79-B4D4-AF68F2A56610Q37350401-8F9CDF5D-0983-43D6-8166-07DFAD83C081Q37648595-6671F0E4-ACCB-4CB9-ACBA-130CC8822EFBQ37798549-68AC2599-6731-48AD-ACD3-0E3DF03B79A5Q38161818-55D42DCE-1CD1-47B1-8653-6B5CBB17EC4DQ38558725-7FE5D89C-DA6B-4A8C-98CD-FD0B68386FC4Q39373577-0C1F175C-B806-4FAB-A573-399A97EF3411Q39802645-676A8AA4-918C-4D90-9540-AFA9AA6EE365Q40684940-5BC5B6EC-7C50-4B11-81CB-F13291F72E76Q41086454-273C5515-8D8A-4786-B0DD-24352E23168AQ47123134-9DE184BD-63A5-4400-9B3A-C8D846CC348DQ48287690-BA401680-6C1F-4FB7-B6CC-C32DDC6CCF7AQ51024877-1E5994BE-ADBD-4BFF-BFAA-1EBFACDFE364Q51372656-FF1F2CB5-5E65-4BD3-84D8-47B21A00025DQ51602611-83B5E87F-749D-4F2F-B132-70E258182FA8
P2860
Early renal changes in hemizygous and heterozygous patients with Fabry's disease.
description
1978 nî lūn-bûn
@nan
1978年の論文
@ja
1978年論文
@yue
1978年論文
@zh-hant
1978年論文
@zh-hk
1978年論文
@zh-mo
1978年論文
@zh-tw
1978年论文
@wuu
1978年论文
@zh
1978年论文
@zh-cn
name
Early renal changes in hemizygous and heterozygous patients with Fabry's disease.
@en
type
label
Early renal changes in hemizygous and heterozygous patients with Fabry's disease.
@en
prefLabel
Early renal changes in hemizygous and heterozygous patients with Fabry's disease.
@en
P2093
P356
P1433
P1476
Early renal changes in hemizygous and heterozygous patients with Fabry's disease.
@en
P2093
P2888
P304
P356
10.1038/KI.1978.32
P407
P577
1978-03-01T00:00:00Z